New Enterprise Associates

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats and digital communication risks. Its cloud-based platform offers real-time threat analytics, intelligence, and comprehensive protection to identify, manage, and mitigate potential cyber threats. ZeroFox's solutions include monitoring for phishing attacks, account compromises, impersonation, and various forms of fraud, ensuring proactive defense through integration with existing security measures. The company also provides specialized services such as employee protection for high-value individuals and election protection for political campaigns and organizations. Established in 2013 and headquartered in Baltimore, Maryland, with additional offices in London, Las Condes, and Bengaluru, ZeroFox serves a diverse range of industries, including financial services, healthcare, technology, and media. By leveraging advanced technology and a global perspective on social media threats, ZeroFox aims to safeguard organizations against the evolving landscape of digital risks.

IonQ, Inc. is a technology company that specializes in the development of general-purpose quantum information computers utilizing a trapped ion approach. Founded in 2015 and based in College Park, Maryland, IonQ focuses on advancing quantum computing capabilities through qubit replication, optical networkability, and optimized algorithms. The company's quantum computers represent a significant shift from classical computing, effectively addressing limitations associated with superposition and entanglement at the atomic level. IonQ provides access to its quantum processors through cloud platforms, offering quantum-computing-as-a-service (QCaaS) to a wide range of customers. Additionally, the company engages in research and development to enhance its quantum technology and supports clients through consulting services aimed at co-developing algorithms for its quantum systems.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats and digital communication risks. Its cloud-based platform offers real-time threat analytics, intelligence, and comprehensive protection to identify, manage, and mitigate potential cyber threats. ZeroFox's solutions include monitoring for phishing attacks, account compromises, impersonation, and various forms of fraud, ensuring proactive defense through integration with existing security measures. The company also provides specialized services such as employee protection for high-value individuals and election protection for political campaigns and organizations. Established in 2013 and headquartered in Baltimore, Maryland, with additional offices in London, Las Condes, and Bengaluru, ZeroFox serves a diverse range of industries, including financial services, healthcare, technology, and media. By leveraging advanced technology and a global perspective on social media threats, ZeroFox aims to safeguard organizations against the evolving landscape of digital risks.

IonQ, Inc. is a technology company that specializes in the development of general-purpose quantum information computers utilizing a trapped ion approach. Founded in 2015 and based in College Park, Maryland, IonQ focuses on advancing quantum computing capabilities through qubit replication, optical networkability, and optimized algorithms. The company's quantum computers represent a significant shift from classical computing, effectively addressing limitations associated with superposition and entanglement at the atomic level. IonQ provides access to its quantum processors through cloud platforms, offering quantum-computing-as-a-service (QCaaS) to a wide range of customers. Additionally, the company engages in research and development to enhance its quantum technology and supports clients through consulting services aimed at co-developing algorithms for its quantum systems.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

IonQ, Inc. is a technology company that specializes in the development of general-purpose quantum information computers utilizing a trapped ion approach. Founded in 2015 and based in College Park, Maryland, IonQ focuses on advancing quantum computing capabilities through qubit replication, optical networkability, and optimized algorithms. The company's quantum computers represent a significant shift from classical computing, effectively addressing limitations associated with superposition and entanglement at the atomic level. IonQ provides access to its quantum processors through cloud platforms, offering quantum-computing-as-a-service (QCaaS) to a wide range of customers. Additionally, the company engages in research and development to enhance its quantum technology and supports clients through consulting services aimed at co-developing algorithms for its quantum systems.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is conducting clinical studies for VTS-270, aimed at treating Niemann-Pick disease type C (NPC), and is also engaged in pre-clinical discovery and development of additional therapies for NPC and other lysosomal storage diseases. Vtesse originated as the first spin-out from Cydan Development, an orphan-drug accelerator that identifies promising therapeutic programs. The company collaborates with the National Institutes of Health (NIH) to advance its clinical studies and is supported by a consortium of experienced investors. Vtesse's management team has a strong background, having participated in the development of over 20 approved drugs and vaccines, which underscores its commitment to addressing the needs of underserved patient populations.

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats and digital communication risks. Its cloud-based platform offers real-time threat analytics, intelligence, and comprehensive protection to identify, manage, and mitigate potential cyber threats. ZeroFox's solutions include monitoring for phishing attacks, account compromises, impersonation, and various forms of fraud, ensuring proactive defense through integration with existing security measures. The company also provides specialized services such as employee protection for high-value individuals and election protection for political campaigns and organizations. Established in 2013 and headquartered in Baltimore, Maryland, with additional offices in London, Las Condes, and Bengaluru, ZeroFox serves a diverse range of industries, including financial services, healthcare, technology, and media. By leveraging advanced technology and a global perspective on social media threats, ZeroFox aims to safeguard organizations against the evolving landscape of digital risks.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is conducting clinical studies for VTS-270, aimed at treating Niemann-Pick disease type C (NPC), and is also engaged in pre-clinical discovery and development of additional therapies for NPC and other lysosomal storage diseases. Vtesse originated as the first spin-out from Cydan Development, an orphan-drug accelerator that identifies promising therapeutic programs. The company collaborates with the National Institutes of Health (NIH) to advance its clinical studies and is supported by a consortium of experienced investors. Vtesse's management team has a strong background, having participated in the development of over 20 approved drugs and vaccines, which underscores its commitment to addressing the needs of underserved patient populations.

D2L Corporation is a learning innovation company founded in 1999 and headquartered in Kitchener, Canada, with additional locations in Toronto, Winnipeg, Maryland, Australia, and the United Kingdom. The company specializes in providing cloud-based learning solutions through its platform, Brightspace, which serves a diverse range of clients, including higher education institutions, K-12 schools, healthcare organizations, government agencies, and enterprise sectors. Brightspace combines usability, integrated analytics, and accessibility to enhance the learning experience, offering tools such as course recommendations, adaptive learning, online grading, and mobile applications that facilitate student engagement. D2L aims to inspire lifelong learning by delivering high-quality educational experiences to over 700 clients and more than 8 million learners globally.

Cerecor Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases. Founded in 2011 and headquartered in Rockville, Maryland, the company is advancing a clinical-stage pipeline that includes therapies for inherited metabolic disorders, such as CERC-801, CERC-802, and CERC-803, which are focused on congenital disorders of glycosylation. Additionally, Cerecor is developing CERC-006, an oral mTOR inhibitor aimed at treating complex lymphatic malformations, and two monoclonal antibodies: CERC-002, targeting the cytokine LIGHT for severe pediatric-onset Crohn's disease, and CERC-007, targeting IL-18 for autoimmune inflammatory diseases like adult onset Still's disease and multiple myeloma. Several of these therapies have received Orphan Drug Designation and Rare Pediatric Disease Designation, qualifying them for expedited review upon FDA approval. Cerecor also offers Millipred, an oral prednisolone for various inflammatory conditions.

NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative immuno-therapeutics utilizing its proprietary Artificial Immune (AIM) technology. This technology is designed to enhance the immune system's ability to generate specific responses to targeted antigens, which is crucial for effective cancer treatment and other immune-mediated diseases. NexImmune's product offerings include AIM101, an injectable therapy for certain solid tumors, and AIM ACT, an adoptive cellular therapy aimed at treating specific hematological malignancies. The company is currently advancing two product candidates in human trials: NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. By focusing on improving the body's T cell responses, NexImmune aims to provide curative therapies for patients facing life-threatening conditions.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats and digital communication risks. Its cloud-based platform offers real-time threat analytics, intelligence, and comprehensive protection to identify, manage, and mitigate potential cyber threats. ZeroFox's solutions include monitoring for phishing attacks, account compromises, impersonation, and various forms of fraud, ensuring proactive defense through integration with existing security measures. The company also provides specialized services such as employee protection for high-value individuals and election protection for political campaigns and organizations. Established in 2013 and headquartered in Baltimore, Maryland, with additional offices in London, Las Condes, and Bengaluru, ZeroFox serves a diverse range of industries, including financial services, healthcare, technology, and media. By leveraging advanced technology and a global perspective on social media threats, ZeroFox aims to safeguard organizations against the evolving landscape of digital risks.

Bravo Health, Inc. is a managed care provider that specializes in offering Medicare Advantage plans, including options tailored for special needs populations such as those receiving institutional care or individuals with chronic health conditions. The company also provides private fee-for-service plans, allowing members the flexibility to choose their healthcare providers, as well as Part D prescription drug plans for those requiring medication coverage. Bravo Health serves members across several states, including Delaware, Maryland, Pennsylvania, Texas, New Jersey, and Washington, D.C., and extends its prescription drug plans to 43 states. Founded in 1996 and based in Baltimore, Maryland, the company was formerly known as Elder Health, Inc.

D2L Corporation is a learning innovation company founded in 1999 and headquartered in Kitchener, Canada, with additional locations in Toronto, Winnipeg, Maryland, Australia, and the United Kingdom. The company specializes in providing cloud-based learning solutions through its platform, Brightspace, which serves a diverse range of clients, including higher education institutions, K-12 schools, healthcare organizations, government agencies, and enterprise sectors. Brightspace combines usability, integrated analytics, and accessibility to enhance the learning experience, offering tools such as course recommendations, adaptive learning, online grading, and mobile applications that facilitate student engagement. D2L aims to inspire lifelong learning by delivering high-quality educational experiences to over 700 clients and more than 8 million learners globally.

Sonatype, Inc. is a provider of software supply chain automation solutions, established in 2008 and headquartered in Fulton, Maryland, with additional offices in McLean, Virginia; London, United Kingdom; and Sydney, Australia. The company offers a comprehensive suite of tools designed to manage and secure software supply chains, including Nexus Lifecycle, Nexus Firewall, Nexus Auditor, Nexus Repository, and Nexus Repository OSS. These solutions help organizations control the flow of components, prevent risky elements from entering the supply chain, monitor applications in production, and efficiently store and distribute software components. Serving a diverse range of industries such as finance, government, technology, insurance, healthcare, and manufacturing, Sonatype supports approximately 70% of the Fortune 100 and is utilized by over 15 million developers globally. Recognized for its innovative workplace culture and growth, Sonatype continues to transform cloud-native development lifecycles, ensuring higher quality, maintainable, and secure software.

Millennial Media Inc. is a prominent provider of mobile advertising solutions, catering to advertisers and developers in the United States and internationally. Founded in 2006 and headquartered in Baltimore, Maryland, the company offers a range of services that enable advertisers to effectively reach and engage their target audiences across various mobile devices. Its offerings include a demand-side platform for direct inventory access, a premium mobile advertising exchange, and tools for designing advertisements. Millennial Media also supports developers with software development kits for various ad formats, ad serving capabilities, and mediation tools that optimize ad requests from multiple sources. Additionally, the company operates MYDAS, a mobile advertising technology that identifies unique users and tailors ad delivery based on interests and behaviors. Millennial Media serves a significant portion of leading advertisers and is recognized for providing an attractive monetization platform for app developers and publishers.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Millennial Media Inc. is a prominent provider of mobile advertising solutions, catering to advertisers and developers in the United States and internationally. Founded in 2006 and headquartered in Baltimore, Maryland, the company offers a range of services that enable advertisers to effectively reach and engage their target audiences across various mobile devices. Its offerings include a demand-side platform for direct inventory access, a premium mobile advertising exchange, and tools for designing advertisements. Millennial Media also supports developers with software development kits for various ad formats, ad serving capabilities, and mediation tools that optimize ad requests from multiple sources. Additionally, the company operates MYDAS, a mobile advertising technology that identifies unique users and tailors ad delivery based on interests and behaviors. Millennial Media serves a significant portion of leading advertisers and is recognized for providing an attractive monetization platform for app developers and publishers.

Optinuity, Inc. specializes in autonomic policy management solutions aimed at enterprises and service providers. The company's flagship product, Optinuity Oasis, enables organizations to create and implement autonomic policies that facilitate self-management of complex business systems. In addition to its software offerings, Optinuity provides a range of professional services, including autonomic policy planning and design, installation and configuration, custom development, and training. The company's solutions are particularly tailored for the financial services, healthcare, and telecommunications sectors. Founded in 2004 and headquartered in Bethesda, Maryland, Optinuity operates as a subsidiary of CA, Inc.

Hillcrest Laboratories is a prominent global supplier of motion processing solutions that utilize MEMS sensors to capture and interpret human and mechanical movement. These advanced technologies enable interaction with various devices and enhance products across consumer technology and industrial sectors. The company is well-known for its contributions to the Smart TV market, having developed HoME, the first pointer-based interactive media system, and the award-winning Loop remote control. Its client base includes notable names such as LG, Roku, and TCL. In addition to its Smart TV roots, Hillcrest has broadened its focus to serve the smartphone and mobile device industries, license technology to leading gaming systems, and provide solutions for virtual reality applications. The company has garnered multiple awards, including several CES Innovations Awards and recognition from PC World and Popular Mechanics. Founded in 2001 in Rockville, Maryland, by Dan Simpkins, Hillcrest Labs is supported by investors such as NEA, Columbia Capital, and Grotech Capital.

Optinuity, Inc. specializes in autonomic policy management solutions aimed at enterprises and service providers. The company's flagship product, Optinuity Oasis, enables organizations to create and implement autonomic policies that facilitate self-management of complex business systems. In addition to its software offerings, Optinuity provides a range of professional services, including autonomic policy planning and design, installation and configuration, custom development, and training. The company's solutions are particularly tailored for the financial services, healthcare, and telecommunications sectors. Founded in 2004 and headquartered in Bethesda, Maryland, Optinuity operates as a subsidiary of CA, Inc.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Sourcefire, Inc. is a provider of enterprise threat management solutions focused on enhancing the cybersecurity of IT infrastructures across various sectors, including healthcare, financial services, manufacturing, energy, education, retail, telecommunications, and government organizations. Founded in 2001 and headquartered in Columbia, Maryland, the company develops both open source and commercial security products. Notably, its offerings include Snort, an open source intrusion prevention technology, and the Sourcefire 3D System, which integrates multiple security solutions such as intrusion prevention, network behavior analysis, and vulnerability assessment within a unified management framework. Additionally, Sourcefire provides ClamAV, an open source anti-virus and anti-malware solution. Alongside its products, the company offers technical support and professional services that encompass network security deployment, customer support, and certification training. Sourcefire markets its products through a direct sales force and through partnerships with resellers, distributors, and original equipment manufacturers.

Optinuity, Inc. specializes in autonomic policy management solutions aimed at enterprises and service providers. The company's flagship product, Optinuity Oasis, enables organizations to create and implement autonomic policies that facilitate self-management of complex business systems. In addition to its software offerings, Optinuity provides a range of professional services, including autonomic policy planning and design, installation and configuration, custom development, and training. The company's solutions are particularly tailored for the financial services, healthcare, and telecommunications sectors. Founded in 2004 and headquartered in Bethesda, Maryland, Optinuity operates as a subsidiary of CA, Inc.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Psyadon Pharmaceuticals, Inc. is engaged in the discovery and development of innovative drugs aimed at addressing psychiatric and neurological diseases. Founded in 2004 and based in Germantown, Maryland, the company specializes in Ecopipam, a drug that selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain. This therapeutic approach is designed to provide treatment options for patients suffering from serious conditions who have limited alternatives. Formerly known as Ruxton Pharmaceuticals, Inc., the company changed its name in October 2008 and currently operates as a subsidiary of Emalex Biosciences, Inc. Psyadon Pharmaceuticals is committed to advancing medical solutions that can significantly benefit individuals with challenging health issues.

Sourcefire, Inc. is a provider of enterprise threat management solutions focused on enhancing the cybersecurity of IT infrastructures across various sectors, including healthcare, financial services, manufacturing, energy, education, retail, telecommunications, and government organizations. Founded in 2001 and headquartered in Columbia, Maryland, the company develops both open source and commercial security products. Notably, its offerings include Snort, an open source intrusion prevention technology, and the Sourcefire 3D System, which integrates multiple security solutions such as intrusion prevention, network behavior analysis, and vulnerability assessment within a unified management framework. Additionally, Sourcefire provides ClamAV, an open source anti-virus and anti-malware solution. Alongside its products, the company offers technical support and professional services that encompass network security deployment, customer support, and certification training. Sourcefire markets its products through a direct sales force and through partnerships with resellers, distributors, and original equipment manufacturers.

Hillcrest Laboratories is a prominent global supplier of motion processing solutions that utilize MEMS sensors to capture and interpret human and mechanical movement. These advanced technologies enable interaction with various devices and enhance products across consumer technology and industrial sectors. The company is well-known for its contributions to the Smart TV market, having developed HoME, the first pointer-based interactive media system, and the award-winning Loop remote control. Its client base includes notable names such as LG, Roku, and TCL. In addition to its Smart TV roots, Hillcrest has broadened its focus to serve the smartphone and mobile device industries, license technology to leading gaming systems, and provide solutions for virtual reality applications. The company has garnered multiple awards, including several CES Innovations Awards and recognition from PC World and Popular Mechanics. Founded in 2001 in Rockville, Maryland, by Dan Simpkins, Hillcrest Labs is supported by investors such as NEA, Columbia Capital, and Grotech Capital.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Iomai Corporation specializes in the discovery and development of vaccines and immune system stimulants using a unique, needle-free approach known as transcutaneous immunization (TCI). This technology utilizes antigen-presenting cells located in the outer layers of the skin to enhance immune responses, allowing for the improvement of existing vaccines and the creation of new ones that can only be administered through this method. Founded in 1997 and based in Gaithersburg, Maryland, Iomai aims to expand the global vaccine market. Following its acquisition by Intercell Ag, the company was rebranded as Intercell USA, Inc. and now operates as a subsidiary of Intercell Biomedical Research & Development AG.